2022
In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease
Bohorquez S, Constantinescu C, Manser P, Gunn R, Russell D, Tonietto M, Bullich S, Stephens A, Mueller A, Klein G, Teng E, Pickthorn K. In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063517.Peer-Reviewed Original ResearchChoroid plexusAlzheimer's diseaseTau pathology distributionModerate AD subjectsTarget cortical regionsTherapeutic trialsTau pathologyHead studiesPathology distributionCentrum semiovaleCortical greyBraak regionsAD subjectsHuman studiesInferior cerebellumSubcortical regionsHead comparisonQuantification scaleCortical regionsSubcortical structuresMinute imagesCSF spaceDiseaseUnimpaired subjectsSUVRIn Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease
Bohorquez S, Constantinescu C, Manser P, Gunn R, Russell D, Tonietto M, Bullich S, Stephens A, Mueller A, Klein G, Teng E, Pickthorn K. In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063513.Peer-Reviewed Original ResearchChoroid plexusAlzheimer's diseaseTau pathology distributionModerate AD subjectsTarget cortical regionsTherapeutic trialsTau pathologyHead studiesPathology distributionCentrum semiovaleCortical greyBraak regionsAD subjectsHuman studiesInferior cerebellumSubcortical regionsHead comparisonQuantification scaleCortical regionsSubcortical structuresMinute imagesCSF spaceDiseaseUnimpaired subjectsSUVR
2010
Poster 14: Evaluation of Novel Radiotracers Targeting Non-Dopaminergic Striatal Biomarkers in HD: 18F-FPEB and PET Imaging for Metabotropic Glutamate Receptor Type 5 (mGluR5) Expression in Healthy Subjects and Subjects with Huntington Disease (HD)
Russell D, Jennings D, Tamagnan G, Seibyl J, Koren A, Zubal G, Marek K. Poster 14: Evaluation of Novel Radiotracers Targeting Non-Dopaminergic Striatal Biomarkers in HD: 18F-FPEB and PET Imaging for Metabotropic Glutamate Receptor Type 5 (mGluR5) Expression in Healthy Subjects and Subjects with Huntington Disease (HD). Neurotherapeutics 2010, 7: 142. DOI: 10.1016/j.nurt.2009.09.016.Peer-Reviewed Original ResearchHD subjectsHuntington's diseaseMGluR5 expressionTemporal lobeHuman studiesStandardized uptake value ratioPET imagingEnkephalinergic striatal neuronsLimbic cortical areasMean SUV ratioEarly brain changesEarly HD patientsUptake value ratioGray matter areasPromising PET radiotracerCerebellar reference regionSymptomatic HD subjectsNon-human primatesHD patientsNeuron lossStriatal neuronsIntense uptakeHealthy controlsBrain changesAge 44